Yahoo Finance Have Insiders Been Buying Biohaven Pharmaceutical Holding Company Ltd. (NYSE:BHVN) Shares?
We often see insiders buying up shares in companies that perform well over the long term. Unfortunately, there are also plenty of examples of share prices declining precipitously after insiders have sold shares. So we'll take a look at whether insiders have been buying or selling shares in Biohaven Pharmaceutical Holding Company Ltd. (NYSE:BHVN).
Do Insider Transactions Matter?
It's quite normal to see company insiders, such as board members, trading in company stock, from time to time. However, such insiders must disclose their trading activities, and not trade on inside information.
We would never suggest that investors should base their decisions solely on what the directors of a company have been doing. But logic dictates you should pay some attention to whether insiders are buying or selling shares. As Peter Lynch said, 'insiders might sell their shares for any number of reasons, but they buy them for only one: they think the price will rise.
See our latest analysis for Biohaven Pharmaceutical Holding
The Last 12 Months Of Insider Transactions At Biohaven Pharmaceutical Holding
In the last twelve months, the biggest single purchase by an insider was when Director John Childs bought US$404k worth of shares at a price of US$40.37 per share. Although we like to see insider buying, we note that this large purchase was at significantly below the recent price of US$52.45. Because it occurred at a lower valuation, it doesn't tell us much about whether insiders might find today's price attractive.
Biohaven Pharmaceutical Holding insiders may have bought shares in the last year, but they didn't sell any. You can see the insider transactions (by individuals) over the last year depicted in the chart below. If you want to know exactly who sold, for how much, and when, simply click on the graph below!
Biohaven Pharmaceutical Holding is not the only stock that insiders are buying. For those who like to find winning investments this free list of growing companies with recent insider purchasing, could be just the ticket.
Insider Ownership of Biohaven Pharmaceutical Holding
Looking at the total insider shareholdings in a company can help to inform your view of whether they are well aligned with common shareholders. I reckon it's a good sign if insiders own a significant number of shares in the company. Biohaven Pharmaceutical Holding insiders own 16% of the company, currently worth about US$443m based on the recent share price. This kind of significant ownership by insiders does generally increase the chance that the company is run in the interest of all shareholders.
So What Does This Data Suggest About Biohaven Pharmaceutical Holding Insiders?
There haven't been any insider transactions in the last three months -- that doesn't mean much. On a brighter note, the transactions over the last year are encouraging. Judging from their transactions, and high insider ownership, Biohaven Pharmaceutical Holding insiders feel good about the company's future. Of course, the future is what matters most. So if you are interested in Biohaven Pharmaceutical Holding, you should check out this free report on analyst forecasts for the company.
Of course, you might find a fantastic investment by looking elsewhere. So take a peek at this free list of interesting companies.
For the purposes of this article, insiders are those individuals who report their transactions to the relevant regulatory body. We currently account for open market transactions and private dispositions, but not derivative transactions.
If you spot an error that warrants correction, please contact the editor at editorial-team@simplywallst.com. This article by Simply Wall St is general in nature. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. Simply Wall St has no position in the stocks mentioned.
We aim to bring you long-term focused research analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Thank you for reading.
